Correlation between allograft survival and chimeric state after bone marrow infusion in rat small bowel transplantation.
Methods to enhance natural microchimerism, which occurs after any successful organ transplant, are currently explored using unmodified donor bone marrow both in experimental and in clinical trials. Because of the potential immunomodulatory effects of donor bone marrow cells, we performed this study to evaluate the effect of single and multiple donor-specific bone marrow infusions (DSBMI) on chimerism and small bowel allograft survival in a fully histoincompatible rat model. Forty-five male DA rats and 45 female Lewis rats were used as donors and recipients, respectively, for a heterotopic small bowel transplant. Animals were separated into 10 groups according to the number of bone marrow infusions and immunosuppressive protocol used. Control groups (groups 1 and 2) did not receive any bone marrow infusion, groups 3 and 4 received one infusion at day 0 (150 x 10(6) cells), groups 5 and 6 received two infusions at days 0 and 4 (75 x 10(6) cells each), groups 7 and 8 received two infusions at days 4 and 10 (75 x 10(6) cells each), and groups 9 and 10 received five infusions at days 4, 10, 15, 20 and 25 (30 x 10(6) cells each). Animals in groups 1, 3, 5, 7 and 9 were immunosuppressed with 0.5 mg/kg FK506 while the remaining groups were immunosuppressed with 1 mg/kg FK506, from day 0 to 4 after transplant. Every 15 days, the chimeric state was determined by flow cytometry in order to detect cells expressing DA rat class I antigen, and small bowel biopsies were obtained from ileostomies. Animals in all groups showed minimal to moderate acute rejection at day 15 after transplant, however, vascular rejection (vasculitis, arteritis) was observed in only bone marrow groups (100% in 0.5 mg/kg and 42.1% in 1 mg/kg FK506 groups). On day 30, 58.3% of bone-marrow-infused animals and 66.6% of controls showed severe acute and early chronic rejection. The chimeric levels varied from 0 to 12% after transplant and were significantly higher in bone-marrow-infused groups compared with controls (p < 0.05). We conclude that modulation of immune response with short-course immunosuppression and a single or multiple DSBMI did not improve allograft or recipient survival. The inability to achieve a stable chimeric state did not allow us to determine the effect of chimerism on graft and recipient survival after small bowel transplantation.
Bakonyi Neto
A
A
Division of Liver/GI Transplantation, University of Miami School of Medicine, Florida, USA.
Ricordi
C
C
Feo
C F
CF
Porcu
A
A
Misiakos
E P
EP
Gandia
C
C
Ruiz
P
P
Bertho
M
M
Carreno
M
M
Esquenazi
V
V
Miller
J
J
Tzakis
A G
AG
D000818:Animals; D001706:Biopsy; D016026:Bone Marrow Transplantation / Q000276:immunology* / Q000379:methods*; D004195:Disease Models, Animal; D005260:Female; D005434:Flow Cytometry; D006084:Graft Rejection / Q000276:immunology / Q000473:pathology; D006085:Graft Survival / Q000276:immunology*; D006650:Histocompatibility Testing / Q000379:methods*; D007165:Immunosuppression Therapy / Q000379:methods*; D007262:Infusions, Intravenous; D007421:Intestine, Small / Q000276:immunology*; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D018183:Transplantation Chimera / Q000276:immunology*; D014184:Transplantation, Homologous / Q000276:immunology*